Home › End Stage Liver Disease › NCT05477277

Adverse Outcomes and Mortality in Liver Transplant

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. All patients with end-stage liver disease undergoing evaluation for liver transplantation
2. Patient clinically indicated for MRI during transplant candidacy evaluation
3. Adult

Exclusion Criteria:

1\. Contra indication to MRI

About the study

Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.

What is being tested

• MAsS (diagnostic test)

Sponsor: Mayo Clinic · Participants: 100 · Started: Nov 2, 2022

Contact the study team

• Latasha Bunkley · Phone: 480.342.5756

Official record on ClinicalTrials.gov — NCT05477277

Locations in the U.S.

Conditions

• End Stage Liver Disease
• Sarcopenia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.